On the contrary, there was no significant correlation between KIF11 expression and the prognosis of BLCA, ESCA, and CESC patients in the group with decreased CD4+ memory T cells and SARC, HNSC, PDAC, LUSC, and STAD patients in the group with enriched CD4+ memory T cells (Figure 10(c)). This evidence concerns the gene KIF11 and bladder transitional cell carcinoma.